Bayer Drug Shows Stroke Prevention Promise

Bayer's experimental blood thinner, asundexian, has shown promising results in a large Phase III trial, effectively reducing both the frequency and severity of recurrent ischemic strokes. The study involving 12,327 patients reported that 6.2% taking asundexian experienced another ischemic stroke compared to 8.4% in the placebo group. Furthermore, strokes that did occur in the asundexian group were less likely to be moderate to severe.

This promising outcome is tempered by a previous setback in 2023 when asundexian did not prevent first strokes in atrial fibrillation patients. However, the latest trial results also indicated low and comparable rates of intracranial and bleeding strokes between the asundexian and placebo groups. Bayer is optimistic about asundexian's potential to offset declining revenue from older drugs like Xarelto, which has lost patent protection and faces generic competition.

Bayer is currently in discussions with global health authorities regarding regulatory approval for asundexian. The company faces competition from Novartis and a joint effort by Bristol Myers Squibb and Johnson & Johnson, both developing similar stroke-prevention drugs. Stroke remains a significant global health challenge, being the third-leading cause of death and disability worldwide.